The TERN-601 obesity trial showed that a once-daily oral small-molecule GLP-1 receptor agonist could produce dose-dependent weight loss, appetite suppression, and delayed gastric emptying—but the program was discontinued after three Phase 2 participants developed liver-enzyme elevations consistent with potential drug-induced liver injury. The findings, published online on July 30, 2026, are important because they expose a central challenge in oral GLP-1 development: a pill must deliver meaningful receptor activity without introducing a new structural or metabolic liability.
TERN-601 was never approved by the U.S. Food and Drug Administration and is no longer an active clinical-development program. Its results should therefore be read as a development case study, not as a treatment option or a recommendation. The published report provides a detailed look at how an oral obesity compound can demonstrate expected pharmacology yet still fail the broader benefit-risk assessment.
For context, GLP1Place has already reviewed the expanding oral GLP-1 drug landscape. TERN-601 adds a different lesson: convenience and early weight loss are not enough if a compound cannot maintain an acceptable safety profile over repeated exposure.
What the TERN-601 obesity trial actually tested
TERN-601 was an investigational, once-daily, oral, nonpeptide GLP-1 receptor agonist developed by Terns Pharmaceuticals. Unlike peptide medicines such as semaglutide, liraglutide, and tirzepatide, TERN-601 was designed as a small molecule that could be administered orally without relying on the absorption technologies required by many peptide drugs.
The published report combined data from a Phase 1 multiple-ascending-dose study and the Phase 2 FALCON study. Both were randomized, double-blind, placebo-controlled clinical investigations in adults with overweight or obesity. The Phase 1 study included a 28-day treatment period. The Phase 2 study evaluated 12 weeks of treatment with different dose-escalation schedules.
The Phase 1 and Phase 2 studies were registered through ClinicalTrials.gov under identifier NCT06854952. The primary report is available through PubMed.
The study populations were adults without diabetes who met body-mass-index criteria for overweight or obesity. Phase 1 participants were generally between 18 and 65 years old, while Phase 2 allowed participants up to 75 years old. People with significant baseline liver-test abnormalities were excluded, which matters when interpreting the later liver findings: the signal emerged in a trial population screened to reduce pre-existing hepatic risk.
Why the compound looked promising at first
TERN-601 produced several pharmacodynamic effects that researchers would expect from effective GLP-1 receptor activation. In Phase 1, treatment was associated with reduced appetite, delayed gastric emptying, and dose-dependent weight loss over 28 days. In Phase 2, doses of at least 500 mg produced significantly greater mean percentage weight loss at Week 12 than placebo.
Those findings established that the compound was not merely detectable in the bloodstream. It was engaging the intended biological pathway in humans. The appetite and gastric-emptying results were directionally consistent with established effects of GLP-1 receptor agonism, while the weight results suggested that oral small-molecule activity could translate into a measurable clinical effect.
However, the article characterized the weight loss as modest, and the trial duration was short relative to the intended use of obesity medicines. A 12-week study can identify early efficacy and common tolerability problems, but it cannot establish whether a chronic medicine will remain safe over the many months or years that obesity treatment may require.
Phase 1 design
In the 28-day Phase 1 multiple-ascending-dose cohorts, participants received TERN-601 or placebo under different titration schedules. The reported target doses were 240 mg, 500 mg, and 740 mg once daily. Doses were escalated from a lower starting amount over the course of the study.
The Phase 1 protocol administered treatment in a fasting state. Researchers measured safety, tolerability, pharmacokinetics, body weight, appetite, and gastric emptying. The design was intended to establish exposure and early biological activity before longer outpatient testing.
Phase 2 FALCON design
The Phase 2 FALCON study included four TERN-601 dosing groups and a placebo group. The reported target regimens were 250 mg once daily, 500 mg once daily, 500 mg once daily with slower titration, and 750 mg once daily. Unlike the Phase 1 study, Phase 2 treatment was administered without regard to food.
The study used dose titration, with the target dose reached at different times depending on the treatment group. The 250 mg group reached its target during Week 3, the standard 500 mg group during Week 6, the slower-titration 500 mg group during Week 9, and the 750 mg group during Week 9.
These dosing details describe the research protocol only. They are not dosing instructions and should not be interpreted as a regimen for personal use.
The liver-safety signal that ended development
The central finding was not gastrointestinal. It was hepatic.
Three Phase 2 participants developed alanine aminotransferase or aspartate aminotransferase elevations consistent with potential drug-induced liver injury. Two cases occurred in the 500 mg once-daily group, and one occurred in the 750 mg group. The elevations began at or after Week 8, and peak values occurred several weeks after the final dose in the reported cases.
The article also identified one potential Hy’s Law case. Hy’s Law is a regulatory concept used in drug-safety assessment when a patient develops substantial hepatocellular injury accompanied by bilirubin elevation without another clear explanation. A potential Hy’s Law case does not automatically prove that a compound caused severe clinical liver failure, but it is a serious development signal because it can indicate a risk of clinically important hepatotoxicity.
The researchers reported that the liver findings led to discontinuation of TERN-601’s clinical development. This is the key distinction between a trial reporting abnormal laboratory results and a program being stopped. The sponsor and investigators judged that the emerging benefit-risk profile did not justify continuing the compound’s development.
| Study element | Reported TERN-601 finding | Why it matters |
|---|---|---|
| Route | Once-daily oral administration | Addresses convenience and injection-avoidance goals |
| Mechanism | Small-molecule GLP-1 receptor agonism | Seeks to reproduce GLP-1 biology without a peptide injection |
| Early efficacy | Dose-dependent weight loss; significant Phase 2 effect at doses of 500 mg or more | Confirms human pharmacologic activity |
| Common tolerability | Dose-related gastrointestinal adverse events | Consistent with the wider GLP-1 class |
| Serious development issue | Three Phase 2 participants with transaminase elevations consistent with potential drug-induced liver injury | Created an important long-term safety question |
| Program outcome | Clinical development discontinued | TERN-601 is not an approved or active obesity medicine |
How to interpret three liver cases in a small Phase 2 study
Three cases may sound numerically small, but safety interpretation is not based only on the raw count. Investigators consider the severity of laboratory abnormalities, timing, dose relationship, biological pattern, alternative explanations, bilirubin changes, dechallenge after stopping treatment, and whether similar findings appeared in earlier or related programs.
The TERN-601 study was not large enough to estimate the final incidence of liver injury in a broad treatment population. A small trial cannot tell us whether the risk would have been common, rare, or restricted to a susceptible subgroup. It also cannot establish whether the findings would have persisted with slower titration, a lower exposure, a different formulation, or a redesigned molecule.
But uncertainty cuts both ways. The absence of enough participants to calculate a stable incidence does not make the signal irrelevant. When liver-test abnormalities appear repeatedly in a controlled trial, particularly when one case may meet a serious regulatory pattern, the finding can be sufficient to stop development while investigators reassess the molecule.
The authors’ conclusion was direct: TERN-601 demonstrated modest dose-dependent weight loss, but the liver-safety findings led to clinical-development discontinuation. That conclusion should carry more weight than summaries that focus only on the fact that the compound reduced body weight.
Why oral small-molecule GLP-1 drugs face a special development challenge
Peptide GLP-1 therapies and oral small-molecule GLP-1 agonists share a target, but they do not necessarily share the same pharmacology, metabolism, tissue distribution, or off-target profile.
Peptide drugs are large biological molecules whose absorption and clearance are shaped by proteolysis, formulation, injection route, and receptor-binding properties. A small molecule must solve a different set of problems. It needs sufficient oral bioavailability, sustained exposure, receptor selectivity, predictable metabolism, and an acceptable interaction profile across multiple organs.
That chemical flexibility can permit tablets with simpler storage and administration requirements. It can also create liabilities because small molecules may interact with hepatic enzymes, transporters, or other biological targets in ways that are not captured by the intended receptor mechanism alone.
The TERN-601 paper places the result in the context of danuglipron and lotiglipron, two other oral small-molecule GLP-1 receptor agonists with similar core scaffold or pharmacophore features that were discontinued after liver-safety concerns. The authors emphasize that TERN-601 had notable pharmacologic differences, but they also argue that the cluster of findings deserves attention when designing and evaluating future nonpeptide GLP-1 compounds.
This does not mean that every oral GLP-1 molecule will have the same problem. Orforglipron, for example, is a chemically distinct small-molecule GLP-1 receptor agonist with its own regulatory evidence base. The relevant lesson is not that oral GLP-1 medicines as a group cause liver injury. The lesson is that oral small-molecule programs cannot assume that efficacy and gastrointestinal tolerability will predict hepatic safety.
TERN-601 compared with other oral GLP-1 development paths
The oral GLP-1 field includes more than one design strategy. Oral semaglutide is a peptide-based medicine formulated for oral delivery. Orforglipron is a small-molecule GLP-1 receptor agonist. Other investigational programs, including TERN-601, have pursued different molecular structures and dosing strategies.
This distinction matters for readers who use the phrase “oral GLP-1” as though it describes a single technology. It does not. The route of administration is the same, but the active molecules can be fundamentally different.
GLP1Place’s overview of the full oral GLP-1 lineup provides broader context. TERN-601 is not simply another entry in a list of oral candidates; it is a discontinued program that provides a cautionary example of how structure-specific safety issues can reshape the field.
| Oral GLP-1 category | Example | Core development question |
|---|---|---|
| Oral peptide GLP-1 | Semaglutide | Can a peptide be protected and absorbed reliably enough for oral use? |
| Small-molecule GLP-1 | Orforglipron | Can a nonpeptide agonist provide durable efficacy with acceptable chronic safety? |
| Discontinued small-molecule program | TERN-601 | Can early efficacy be retained without important liver-safety signals? |
| Other investigational small molecules | Multiple pipeline candidates | Which molecular designs separate oral convenience from structure-specific toxicity? |
Development and regulatory implications
The TERN-601 outcome is unlikely to end research into oral GLP-1 medicines. However, it reinforces the scrutiny applied to the chemistry behind each program. Developers must show not only receptor potency and weight-loss activity but also evidence on hepatic metabolism, reactive metabolites, transporter interactions, exposure margins, and the relationship between dose escalation and liver-test abnormalities.
A development program may prioritize molecules with cleaner liver-safety findings even if they show less striking early efficacy. In chronic obesity treatment, a compound’s ability to sustain an acceptable benefit-risk profile is as important as its short-term weight-loss result.
For clinical-trial investigators, the report reinforces the role of scheduled laboratory testing during early exposure and dose-escalation studies. It also illustrates why follow-up after treatment cessation can matter: the reported peak liver-enzyme elevations occurred several weeks after the final dose in some participants.
Regulatory and compliance notes
TERN-601 was investigational and was not approved for human treatment. The research doses and titration schedules reported in the paper are historical clinical-trial details, not instructions for personal use.
Regulatory review distinguishes between an observed laboratory signal and a confirmed diagnosis of clinical liver injury. The TERN-601 publication uses cautious language, describing the findings as consistent with potential drug-induced liver injury. That wording should be preserved. The data justified discontinuation and scientific attention, but they do not establish the exact mechanism or prove that every abnormality was caused exclusively by TERN-601.
Readers should not confuse the TERN-601 outcome with a class-wide FDA warning against all GLP-1 medicines. The publication concerns one discontinued investigational small molecule. It does not change the approval status, labeling, or evidence base for approved GLP-1 therapies.
Researcher takeaways
- Early receptor activity is not enough. TERN-601 produced expected GLP-1 pharmacodynamic effects, but development still stopped because of liver-safety findings.
- Short trials can reveal serious liabilities. The relevant transaminase elevations appeared during the 12-week Phase 2 study, with some peaks occurring after the final dose.
- Small-molecule structure matters. Oral delivery does not define a single pharmacologic class. Each compound requires its own metabolism and safety assessment.
- Slow titration may not answer every safety question. The FALCON study included different titration schedules, yet the program still encountered liver findings.
- Weight-loss percentages need context. The study demonstrated statistically significant early efficacy at some doses, but the publication described the overall effect as modest and the treatment period was short.
- Potential Hy’s Law cases change the development conversation. Even when participant numbers are small, serious hepatic patterns can outweigh promising preliminary efficacy.
Consumer awareness notes
TERN-601 is not an approved medication, and its discontinuation means there is no validated clinical role for it in obesity treatment. A published clinical trial does not mean that a compound is available for routine use; it means that researchers tested a defined material under a defined protocol in a monitored study.
The product identity, formulation, laboratory testing, eligibility criteria, safety monitoring, and follow-up in a clinical trial may not exist outside the research setting. The TERN-601 findings also illustrate why “oral” should not be treated as synonymous with “safer.” A tablet may be more convenient than an injection, but convenience does not determine hepatic metabolism, off-target activity, or long-term tolerability.
For general education, readers can compare this result with GLP1Place’s discussion of the latest GLP-1 safety evidence. The studies address different questions and should not be merged into one generalized risk claim. TERN-601 concerns a discontinued investigational small molecule; the other article addresses safety signals in approved GLP-1 treatment populations.
What happens next for TERN-601 research?
Because clinical development was discontinued, the most useful future work may involve mechanistic analysis rather than additional efficacy trials. Researchers may examine whether the liver findings were linked to a metabolite, exposure threshold, molecular scaffold, patient susceptibility, or an interaction among these factors.
Further analysis could help determine whether the signal was pharmacologically related to GLP-1 receptor activation or chemically independent of the receptor mechanism. That distinction is important. If the problem is primarily structure-specific, future molecules may avoid it. If the signal reflects a broader property of a subgroup of oral GLP-1 agonists, developers may need new screening methods across the category.
The publication suggests that the experience with TERN-601, danuglipron, and lotiglipron should inform molecular design, dose titration, and safety evaluation for future oral small-molecule GLP-1 programs. In that sense, a discontinued compound can still contribute useful scientific knowledge when results are reported clearly and interpreted cautiously.
FAQ
What is TERN-601?
TERN-601 was an investigational once-daily oral small-molecule GLP-1 receptor agonist developed for adults with overweight or obesity. It was tested in Phase 1 and Phase 2 clinical studies and was not approved by the FDA.
Did TERN-601 produce weight loss?
Yes. The Phase 1 study found dose-dependent weight loss over 28 days, and Phase 2 doses of 500 mg or more produced significantly greater mean percentage weight loss at Week 12 than placebo. The published report described the overall effect as modest.
Why was the TERN-601 program stopped?
Three Phase 2 participants developed transaminase elevations consistent with potential drug-induced liver injury. The report also identified one potential Hy’s Law case. These liver-safety findings led to discontinuation of clinical development.
Does TERN-601 show that all oral GLP-1 drugs damage the liver?
No. The findings concern one investigational molecule and do not establish a class-wide conclusion. They do show why each oral small-molecule GLP-1 receptor agonist requires independent long-term safety evaluation.
Was TERN-601 ever approved?
No. TERN-601 was an investigational compound and was not approved for obesity, diabetes, or any other indication.
What is the main lesson from the TERN-601 obesity trial?
The main lesson is that oral GLP-1 development must balance efficacy, tolerability, pharmacokinetics, and organ-specific safety. Early weight loss and expected GLP-1 effects cannot compensate for a potentially important liver-safety signal.